Teva Pharma (NYSE: TEVA) reported Q2 EPS of $0.02, $0.60 worse than the analyst estimate of $0.62. Revenue for the quarter came in at $4.14 billion versus the consensus estimate of $4.05 billion.

GUIDANCE:

Teva Pharma sees FY2026 EPS of $1.91-$2.11, versus the consensus of $2.16. Teva Pharma sees FY2026 revenue of $16.5-16.85 billion, versus the consensus of $16.63 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.